Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.748
+0.087 (13.10%)
Mar 12, 2025, 2:51 PM EST - Market open
Prelude Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 7 | - | - | - | - | |
| Gross Profit | 7 | - | - | - | - | |
| Selling, General & Admin | 28.72 | 28.88 | 30.65 | 26.96 | 10.59 | |
| Research & Development | 118 | 103.39 | 92.89 | 86.78 | 48.18 | |
| Operating Expenses | 146.71 | 132.28 | 123.54 | 113.74 | 58.76 | |
| Operating Income | -139.71 | -132.28 | -123.54 | -113.74 | -58.76 | |
| Other Non Operating Income (Expenses) | 12.54 | 10.45 | 8.1 | 2.04 | 1.83 | |
| Pretax Income | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | |
| Net Income | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | |
| Net Income to Common | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | |
| Shares Outstanding (Basic) | 76 | 60 | 47 | 46 | 12 | |
| Shares Outstanding (Diluted) | 76 | 60 | 47 | 46 | 12 | |
| Shares Change (YoY) | 25.60% | 27.41% | 2.87% | 269.03% | 647.86% | |
| EPS (Basic) | -1.68 | -2.02 | -2.44 | -2.43 | -4.56 | |
| EPS (Diluted) | -1.68 | -2.02 | -2.44 | -2.43 | -4.56 | |
| Free Cash Flow | -103.65 | -110.58 | -86.75 | -85.85 | -46.8 | |
| Free Cash Flow Per Share | -1.37 | -1.83 | -1.83 | -1.86 | -3.75 | |
| Gross Margin | 100.00% | - | - | - | - | |
| Operating Margin | -1995.91% | - | - | - | - | |
| Profit Margin | -1816.76% | - | - | - | - | |
| Free Cash Flow Margin | -1480.74% | - | - | - | - | |
| EBITDA | -137.94 | -131.11 | -122.22 | -112.82 | -58.22 | |
| D&A For EBITDA | 1.77 | 1.17 | 1.32 | 0.92 | 0.54 | |
| EBIT | -139.71 | -132.28 | -123.54 | -113.74 | -58.76 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.